291 related articles for article (PubMed ID: 36401041)
21. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
[TBL] [Abstract][Full Text] [Related]
22. CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice.
Xu L; Park KH; Zhao L; Xu J; El Refaey M; Gao Y; Zhu H; Ma J; Han R
Mol Ther; 2016 Mar; 24(3):564-9. PubMed ID: 26449883
[TBL] [Abstract][Full Text] [Related]
23. Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice.
Xu L; Lau YS; Gao Y; Li H; Han R
Mol Ther; 2019 Aug; 27(8):1407-1414. PubMed ID: 31129119
[TBL] [Abstract][Full Text] [Related]
24. CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives.
Chen G; Wei T; Yang H; Li G; Li H
Cells; 2022 Sep; 11(19):. PubMed ID: 36230926
[TBL] [Abstract][Full Text] [Related]
25. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
[TBL] [Abstract][Full Text] [Related]
26. CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.
Zhang Y; Long C; Li H; McAnally JR; Baskin KK; Shelton JM; Bassel-Duby R; Olson EN
Sci Adv; 2017 Apr; 3(4):e1602814. PubMed ID: 28439558
[TBL] [Abstract][Full Text] [Related]
27. A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing.
Zhang Y; Li H; Nishiyama T; McAnally JR; Sanchez-Ortiz E; Huang J; Mammen PPA; Bassel-Duby R; Olson EN
Mol Ther Nucleic Acids; 2022 Sep; 29():525-537. PubMed ID: 36035749
[TBL] [Abstract][Full Text] [Related]
28. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
Erkut E; Yokota T
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
[TBL] [Abstract][Full Text] [Related]
29. In vivo gene editing in dystrophic mouse muscle and muscle stem cells.
Tabebordbar M; Zhu K; Cheng JKW; Chew WL; Widrick JJ; Yan WX; Maesner C; Wu EY; Xiao R; Ran FA; Cong L; Zhang F; Vandenberghe LH; Church GM; Wagers AJ
Science; 2016 Jan; 351(6271):407-411. PubMed ID: 26721686
[TBL] [Abstract][Full Text] [Related]
30. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.
Nelson CE; Wu Y; Gemberling MP; Oliver ML; Waller MA; Bohning JD; Robinson-Hamm JN; Bulaklak K; Castellanos Rivera RM; Collier JH; Asokan A; Gersbach CA
Nat Med; 2019 Mar; 25(3):427-432. PubMed ID: 30778238
[TBL] [Abstract][Full Text] [Related]
31. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
[TBL] [Abstract][Full Text] [Related]
32. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9.
Koo T; Lu-Nguyen NB; Malerba A; Kim E; Kim D; Cappellari O; Cho HY; Dickson G; Popplewell L; Kim JS
Mol Ther; 2018 Jun; 26(6):1529-1538. PubMed ID: 29730196
[TBL] [Abstract][Full Text] [Related]
33. Questions Answered and Unanswered by the First CRISPR Editing Study in a Canine Model of Duchenne Muscular Dystrophy.
Wasala NB; Hakim CH; Chen SJ; Yang NN; Duan D
Hum Gene Ther; 2019 May; 30(5):535-543. PubMed ID: 30648435
[TBL] [Abstract][Full Text] [Related]
34. From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method.
DuchĂȘne B; Iyombe-Engembe JP; Rousseau J; Tremblay JP; Ouellet DL
Methods Mol Biol; 2018; 1687():267-283. PubMed ID: 29067670
[TBL] [Abstract][Full Text] [Related]
35. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.
Min YL; Li H; Rodriguez-Caycedo C; Mireault AA; Huang J; Shelton JM; McAnally JR; Amoasii L; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2019 Mar; 5(3):eaav4324. PubMed ID: 30854433
[TBL] [Abstract][Full Text] [Related]
36. CRISPR Correction of Duchenne Muscular Dystrophy.
Min YL; Bassel-Duby R; Olson EN
Annu Rev Med; 2019 Jan; 70():239-255. PubMed ID: 30379597
[TBL] [Abstract][Full Text] [Related]
37. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.
Long C; Amoasii L; Mireault AA; McAnally JR; Li H; Sanchez-Ortiz E; Bhattacharyya S; Shelton JM; Bassel-Duby R; Olson EN
Science; 2016 Jan; 351(6271):400-3. PubMed ID: 26721683
[TBL] [Abstract][Full Text] [Related]
38. AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice.
Nance ME; Shi R; Hakim CH; Wasala NB; Yue Y; Pan X; Zhang T; Robinson CA; Duan SX; Yao G; Yang NN; Chen SJ; Wagner KR; Gersbach CA; Duan D
Mol Ther; 2019 Sep; 27(9):1568-1585. PubMed ID: 31327755
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
[TBL] [Abstract][Full Text] [Related]
40. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.
Ousterout DG; Kabadi AM; Thakore PI; Majoros WH; Reddy TE; Gersbach CA
Nat Commun; 2015 Feb; 6():6244. PubMed ID: 25692716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]